Futuristic Approaches to Disarming Nicotine Addiction: A Narrative Review of Emerging Therapies
Chetan Vinay Deshmukh, Vibhuti Dilip Mistry, Prakash Maruti Kasbe, Mayuri Bhikaji Nepale, Snehal Sakharam Patil, Shivani Sanjay Ahirrao
Journal of Indian Association of Public Health Dentistry April 6, 2026 DOI: 10.4103/jiaphd.jiaphd_185_25 (opens in new tab) via DOAJ
Summary
AI-generated from the abstractNicotine addiction remains a major global health problem, and existing treatments have limited long-term success because nicotine strongly alters brain reward pathways. This narrative review examines emerging experimental approaches, including nicotine vaccines, CRISPR gene editing, psychedelic-assisted therapy, and brain-computer interfaces, that aim to counteract nicotine's effects or rewire addiction-related brain circuits. The authors argue that these strategies, though still experimental, could make nicotine both physiologically ineffective and psychologically irrelevant by targeting dopaminergic and serotonergic systems.
Study at a glance
| Characteristics | Narrative review Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Crispr Dopamine modulation Neurofeedback Nicotine addiction |
| Key finding | Proposes that emerging biotechnological and neuroscientific interventions, such as nicotine vaccines, CRISPR gene modulation, psychedelic-assisted therapy, and brain-computer interfaces, may disrupt nicotine addiction at molecular and systems levels. |
Abstract
Nicotine addiction is a major contributor to preventable morbidity and mortality globally, forming the biological basis of the tobacco pandemic. Despite the availability of nicotine replacement therapies and behavioral interventions, relapse rates remain high due to nicotine’s profound impact on neurochemical reward pathways. To explore and review novel and emerging treatment modalities that target nicotine dependence through advanced neuroscientific and biotechnological interventions, a narrative review approach was adopted to analyze and synthesize the current literature on innovative therapeutic strategies, including nicotine vaccines, CRISPR gene modulation, psychedelic-assisted therapy, and brain-computer interface applications. The focus was on interventions targeting the dopaminergic and serotonergic systems involved in addiction. Emerging modalities show promise in not only antagonizing nicotine’s pharmacological effects but also in rewiring brain circuits responsible for reward and reinforcement. Techniques such as gene editing and neurotechnology are being investigated for their potential to disrupt the addictive cycle at a molecular and systems level. Advances in neuroscience, pharmacology, and bioengineering present a transformative potential to overcome nicotine addiction. These futuristic strategies, although currently experimental, provide a scientifically grounded roadmap for making nicotine both physiologically ineffective and psychologically irrelevant.